Seven Eight Capital, LP Sage Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $458,238 - $663,239	24,610 Added 117.84%	45,494 $852,000
Q4 2023 Feb 13, 2024	SELL	$17.1 - $22.26 $371,890 - $484,110	-21,748 Reduced 51.01%	20,884 $452,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $714,086 - $2.09 Million	42,632 New	42,632 $877,000
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $755,912 - $960,902	-20,397 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $310,002 - $441,749	7,700 Added 60.64%	20,397 $904,000
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $696,811 - $1.01 Million	12,697 New	12,697 $721,000
Q1 2020 May 14, 2020	SELL	$26.15 - $77.24 $2.02 Million - $5.95 Million	-77,074 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $4.64 Million - $11.9 Million	77,074 New	77,074 $5.56 Million
Q1 2018 May 14, 2018	SELL	$152.15 - $192.33 $331,687 - $419,279	-2,180 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$60.72 - $167.34 $132,369 - $364,801	2,180	2,180 $359,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.